AUAUniversity American Urological Association

Germline Testing in GU Cancers – How I Do It

CME Available: https://auau.auanet.org/node/39544

ACKNOWLEDGEMENTS:
This series is supported by independent educational grants from: 
AstraZeneca
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC 
Lantheus Medical Imaging
Merck & Co., Inc.

LEARNING OBJECTIVES:
At the conclusion of this activity, participants will be able to:
1. Differentiate between germline and somatic testing in the context of GU cancers, understanding the fundamental differences in the types of genetic alterations detected and their implications for patients and their families.
2. Describe the genetic counseling process and the importance of pre-test counseling to discuss the benefits, limitations, and potential implications of germline testing.
3. Evaluate the clinical significance and impact of germline testing results on treatment decisions, surveillance recommendations, and family management.

The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer:

Treatment Intensification for Advanced Prostate Cancer

CME Available: https://auau.auanet.org/node/39486

At the conclusion of these activities, participants will be able to:
1. Identify the latest developments in hormone therapy for advanced prostate cancer, including the use of novel treatments and combinations.
2. Discuss the concept of doublet and triplet therapy in advanced prostate cancer and its rationale in enhancing treatment efficacy.
3. Consider the challenges and future directions in implementing doublet and triplet therapy in clinical practice, including cost, accessibility, and patient selection.

This series is supported by independent educational grants from:
Astellas and Pfizer, Inc.
AstraZeneca
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Lantheus Medical Imaging
Merck & Co., Inc.

REFERENCES:
Freedland SJ, et al. Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer. NEJM Evidence. 2023.

Smith MR, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med 2022.

Fizazi K, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet. 2022.

Clarke NW, et al. Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. NEJM Evidence. 2022

Chi KN, et al. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2023.

Agarwal N, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet. 2023.

PARPi: Precision Medicine in Advanced Prostate Cancer (2023)

CME Available: https://auau.auanet.org/node/39597

At the conclusion of this activity, the learner will be able to:
1. Describe the mechanism of action of PARP inhibitors and the differences among drugs in this class.
2. Describe the role of PARPi treatment alone and in combination with other cancer based therapies.
3. Discuss existing clinical trial data assessing the efficacy of PARPi in advanced prostate cancer and ongoing late phase trials for PARP inhibitors.
4. Recognize the need for a multidisciplinary team to provide care for patients with advanced prostate cancer.

ACKNOWLEDGEMENT
This educational activity is supported by an independent educational grant from:
Pfizer, Inc.

Prostate Cancer Treatment Intensification

Moderator: Dr. Jay D. Raman
Guest: Dr. Michael S. Cookson

Acknowledgement: This podcast was funded by and in collaboration with AZ. All opinions are that of the faculty and do not necessarily reflect those of AstraZeneca.

Release Date: 11/8/2023
Expiration Date: 11/8/2024

Update Series (2023) Lesson 33: A Critical Appraisal of the 2021 AUA/SUFU Guideline on Adult Neurogenic Lower Urinary Tract Dysfunction

Now in its 42nd installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology.

For more information, please visit the AUA Update Series on the AUAUniversity: auau.auanet.org/update23

Disparities in Care and Barriers to Access for Patients with Advanced Prostate Cancer

CME Available: https://auau.auanet.org/node/39088

At the conclusion of these activities, participants will be able to:
1. Recognize current patterns of use for systemic therapies in patients with advanced prostate cancer.
2. Identify disparities in access to care with respect to advanced prostate cancer treatment (ie. race, geography, socioeconomics).
3. Understand opportunities to improve quality and compliance with ADT treatment across different treatment populations.
4. Appreciate financial challenges that may be associated with current therapy options for advanced prostate cancer.
5. Apply treatment approaches that improve patient adherence to ADT including use of oral and parenteral therapies.

ACKNOWLEDGEMENTS:
This series is supported by independent educational grants from:
Myovant Sciences LTD
Pfizer, Inc.

REFERENCES:
Benjamin, D.J., Shrestha, A., Fellman, D. et al. Hormonal treatment for newly diagnosed metastatic prostate cancer: a population-based study from the California cancer registry. Prostate Cancer Prostatic Dis (2023). https://doi.org/10.1038/s41391-023-00732-9

Cortese BD, Dusetzina SB, Al Hussein Al Awamlh B, Penson DF, Chang SS, Barocas DA, Luckenbaugh AN, Scarpato KR, Moses KA, Talwar R. Estimating the Impact of the Inflation Reduction Act on the Out-of-Pocket Costs for Medicare Beneficiaries With Advanced Prostate Cancer. Urol Pract. 2023 Sep;10(5):476-483. doi: 10.1097/UPJ.0000000000000425. Epub 2023 Jul 3. PMID: 37409930.